Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.

An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and ...

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse ...

Oncology nurses and APPs can help reduce discrimination faced by patients with cancer who are members of the LGBTQIA+ ...

Retifanlimab-dlwr (Zynyz) was granted approval from the FDA for treatment of locally recurrent or metastatic squamous cell ...

Adding olanzapine (Zyprexa) to a standard antiemetic regimen displayed safety and efficacy in preventing radiation-induced nausea and vomiting (RINV) for patients receiving abdominal/pelvic ...